which if it reaches the market would be a rival to Novartis’ Lutathera (lutetium [177Lu] oxodotreotide), approved as a second-line therapy for GEP-NETs and due to be filed shortly as first-line ...

The biotech is trying to pick itself up in the wake of the failure of the PARADIGME study of Betalutin (177Lu lilotomab satetraxetan) – an anti-CD37 antibody radionuclide conjugate being tested ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

According to Adam B. Weiner, MD, a urologist at Cedars-Sinai Medical Center, men should begin prostate cancer screening around ages 50 to 55. Former President Joe Biden has been diagnosed with grade ...

The AMPLIFY trial evaluates 64Cu-SAR-bisPSMA's efficacy in detecting prostate cancer lesions in patients with biochemical recurrence. 64Cu-SAR-bisPSMA has received FDA fast track designation for PET ...

The PSMAfore study of 177Lu-PSMA-617 in mCRPC patients showed that higher baseline and on-treatment ctDNA fraction was associated with shorter radiographic progression-free survival (rPFS) and overall ...

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...